These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12756135)

  • 21. Differentiating symptomatic Parkin mutations carriers from patients with idiopathic Parkinson's disease: contribution of automated segmentation neuroimaging method.
    Bilgic B; Bayram A; Arslan AB; Hanagasi H; Dursun B; Gurvit H; Emre M; Lohmann E
    Parkinsonism Relat Disord; 2012 Jun; 18(5):562-6. PubMed ID: 22445249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset-related subtypes of Parkinson's disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study.
    Liu SY; Wu JJ; Zhao J; Huang SF; Wang YX; Ge JJ; Wu P; Zuo CT; Ding ZT; Wang J
    Parkinsonism Relat Disord; 2015 Dec; 21(12):1448-53. PubMed ID: 26559130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
    Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
    Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography.
    Nagasawa H; Saito H; Kogure K; Hatazawa J; Itoh M; Fujiwara T; Watanuki S; Seo S; Iwata R; Ido T
    J Neurol Sci; 1993 Apr; 115(2):136-43. PubMed ID: 8482975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography.
    Nagasawa H; Tanji H; Itoyama Y; Saito H; Kimura I; Fujiwara T; Iwata R; Itoh M; Ido T
    J Neurol Sci; 1996 Dec; 144(1-2):70-6. PubMed ID: 8994106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.
    Ruottinen HM; Rinne JO; Haaparanta M; Solin O; Bergman J; Oikonen VJ; Järvelä I; Santavuori P
    J Neurol Neurosurg Psychiatry; 1997 Jun; 62(6):622-5. PubMed ID: 9219750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy.
    Rinne JO; Burn DJ; Mathias CJ; Quinn NP; Marsden CD; Brooks DJ
    Ann Neurol; 1995 May; 37(5):568-73. PubMed ID: 7755350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations.
    de la Fuente-Fernández R; Pal PK; Vingerhoets FJ; Kishore A; Schulzer M; Mak EK; Ruth TJ; Snow BJ; Calne DB; Stoessl AJ
    J Neural Transm (Vienna); 2000; 107(1):49-57. PubMed ID: 10809403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced uptake of [¹⁸F]FDOPA PET in asymptomatic welders with occupational manganese exposure.
    Criswell SR; Perlmutter JS; Videen TO; Moerlein SM; Flores HP; Birke AM; Racette BA
    Neurology; 2011 Apr; 76(15):1296-301. PubMed ID: 21471467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.
    Wu RM; Shan DE; Sun CM; Liu RS; Hwu WL; Tai CH; Hussey J; West A; Gwinn-Hardy K; Hardy J; Chen J; Farrer M; Lincoln S
    Mov Disord; 2002 Jul; 17(4):670-5. PubMed ID: 12210855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].
    Puñal-Riobóo J; Serena-Puig A; Varela-Lema L; Alvarez-Páez AM; Ruano-Ravina A
    Rev Esp Med Nucl; 2009; 28(3):106-13. PubMed ID: 19558950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus.
    Brück A; Portin R; Lindell A; Laihinen A; Bergman J; Haaparanta M; Solin O; Rinne JO
    Neurosci Lett; 2001 Sep; 311(2):81-4. PubMed ID: 11567783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease.
    Menza MA; Mark MH; Burn DJ; Brooks DJ
    J Neuropsychiatry Clin Neurosci; 1995; 7(2):176-9. PubMed ID: 7626960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorodopa is a Promising Fluorine-19 MRI Probe for Evaluating Striatal Dopaminergic Function in a Rat Model of Parkinson's Disease.
    Yanagisawa D; Oda K; Inden M; Morikawa S; Inubushi T; Taniguchi T; Hijioka M; Kitamura Y; Tooyama I
    J Neurosci Res; 2017 Jul; 95(7):1485-1494. PubMed ID: 27792255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations.
    Scherfler C; Khan NL; Pavese N; Lees AJ; Quinn NP; Brooks DJ; Piccini PP
    Mov Disord; 2006 Jun; 21(6):783-8. PubMed ID: 16511856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.
    Pavese N; Moore RY; Scherfler C; Khan NL; Hotton G; Quinn NP; Bhatia KP; Wood NW; Brooks DJ; Lees AJ; Piccini P
    Exp Neurol; 2010 Mar; 222(1):120-4. PubMed ID: 20043906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.